Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Grand Pharmaceutical Group Limited has announced the acceptance of their Phase III clinical trial application for ITM-11 in China, targeting the treatment of gastroenteropancreatic neuroendocrine tumors. The drug, which has been designated as an orphan drug by the FDA and EMA, is part of a larger portfolio of 12 innovative products the company has in the nuclear medicine anti-tumor market. With trials progressing and a strategic plan in place, Grand Pharmaceutical is emerging as a leader in the field with a comprehensive oncology diagnosis and treatment platform.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.